BioSpace News Archive

Structure Therapeutics Inc. today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent corporate achievements.

Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to share additional data from its diagnostic 64Cu-SAR-bisPSMA trial, COBRA.

Scientific Industries, Inc. announced the appointment of John Nicols to the Board of Directors of SI and Chairman of its wholly, owned subsidiary, Scientific Bioprocessing Inc., effective March 4, 2024.

LGBTQ+ individuals have unique skin care needs, including concerns about sexually transmitted infections, like HIV, as well as acne and hair growth and removal, especially relating to hormone replacement therapy.

Dallas-based board-certified dermatologist Seemal R. Desai, MD, FAAD, will begin his one-year term as president of the American Academy of Dermatology at the close of the AAD’s Annual Meeting.

Dermavant Sciences announced new data on treatment of patients with skin of color from its Phase 3, ADORING 1 and ADORING 2 pivotal trials of VTAMA® cream, 1% in adults and children 2 years of age and older with atopic dermatitis at the 2024 American Academy of Dermatology Annual Meeting, being held from March 8-12 in San Diego, CA.

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its participation in the 36th Annual Roth Conference being held March 17-19, 2024 in Dana Point, California.

NurExone Biologic Inc., a pioneering biopharmaceutical company, finalized a lease and constructing agreement for nearly 200 square meters of laboratories and office space on the campus of the prestigious Israel Institute of Technology.

Akero Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a public offering price of $29.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,650,000 shares of common stock in this offering.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.